Aurum Biosciences
Glasgow
About Aurum Biosciences
AURUM Biosciences Ltd develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need. Aurum is currently completing preclinical development of ABL101, its lead stroke management product, and envisages initiating clinical studies of efficacy and safety in the near future. Follow-on programmes include products for heart disease, cancer, epilepsy, and dementia. Aurum’s lead project utilises an oxygen carrier and proprietary software for use with MRI in Acute Ischaemic Stroke. Aurum has funding in place to initiate recruitment for a Phase 2 clinical study in stroke patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.4M
- Last round: Series Unknown (Jan 2024)
- Website: aurumbiosciences.com
- Phone: +44 141 582 1212
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/aurum-biosciences-150660 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.